Business Wire

Encoded Therapeutics Addresses Common Source of Gene Therapy Toxicity While Achieving Precise Brain Expression in Non-Human Primates, Presented at the American Society of Gene ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics announced today the presentation of non-human primate (NHP) validation of the company’s technology to drive desired gene and protein ...
Yahoo Finance

New Preclinical Data from Encoded Therapeutics Demonstrate Therapeutic Potential of its One-time, Non-opioid Gene Therapy Candidate for Chronic Pain

Preclinical data show the vectorized miRNA candidate achieved durable knockdown of SCN9A (NaV1.7), a genetically validated pain target historically difficult to modulate In non-human primates, ...
Morningstar%2c Inc.

Encoded Therapeutics Presents New Preclinical Data at ASGCT 2026 Highlighting Precision Vector Engineering Across Neurology Programs

– NociPro enables highly selective nociceptor targeting and potent NaV1.7 knockdown in rodents and non-human primates, supporting development candidate ETX301 for post‑amputation neuroma pain – – ...
Business Wire

Encoded Therapeutics Strengthens Clinical Leadership Team with Appointment of Professor Joseph Sullivan, M.D., as Vice President of Clinical Development

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today ...
MarketWatch

Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome

Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...